Seer, Inc. — FY 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the provided text does not give standalone fourth-quarter results.
Business context
Seer is an early-stage life sciences company commercializing the Proteograph Product Suite, which combines proprietary engineered nanoparticles, an automation instrument and software for research-use-only proteomics analysis. Broad commercialization began in January 2022. Seer shipped 22 instruments during 2022, bringing cumulative system shipments to 39 at year-end. The company remains focused on research applications and has not positioned the product for clinical diagnosis.
Financial performance
| Metric | FY 2022 | FY 2021 | Change |
|---|---|---|---|
| Total revenue | $15.5 million | $6.6 million | +134% |
| Gross profit | $7.1 million | $3.4 million | +108% |
| Gross margin | 45.8% | 51.6% | Down 5.8 percentage points |
| Research and development | $45.8 million | $29.1 million | +57% |
| Selling, general and administrative | $58.5 million | $45.8 million | +28% |
| Operating loss | $(97.2) million | $(71.5) million | Loss widened |
| Net loss | $(93.0) million | $(71.2) million | Loss widened 31% |
| Net loss per share, basic and diluted | $(1.49) | $(1.17) | Loss per share increased |
| Cash used in operating activities | $(60.8) million | $(46.3) million | Cash use increased |
FY 2022 revenue comprised $8.6 million of product revenue, $0.9 million of service revenue, $5.2 million classified as related-party revenue, and $0.8 million of grant and other revenue. Higher product sales drove the increase, while cost of revenue rose faster than revenue, contributing to lower gross margin. Operating expenses increased as Seer expanded product development, commercialization, staffing and facilities. Interest income increased to $4.6 million from $0.3 million, partially offsetting the higher operating loss.
Cash, liquidity and obligations
At December 31, 2022, Seer reported $53.2 million of cash and cash equivalents and $373.2 million of investments, totaling $426.4 million. Total current assets were $435.0 million and total current liabilities were $12.6 million. Stockholders’ equity was $447.0 million; accumulated deficit was $219.5 million. The filing reports no borrowings; operating lease liabilities totaled $29.9 million, including $1.8 million current and $28.0 million noncurrent. The company also had $5.7 million of supplier purchase commitments.
Cash, cash equivalents and restricted cash declined by $179.6 million during 2022. Investing cash use included $112.6 million of net purchases of available-for-sale securities and $10.3 million of property and equipment. This cash-flow movement should be considered alongside the company’s investment balances. Management stated that available liquidity was expected to fund operations for at least 12 months from the filing/financial-statement issuance date, while also expecting continued losses and negative operating cash flow for the foreseeable future.
Material changes and unusual items
- Revenue more than doubled, but the company remained substantially loss-making; net loss increased from $71.2 million to $93.0 million.
- Revenue concentration remains significant: PrognomiQ accounted for 32% of FY 2022 revenue, compared with 35% in 2021. The filing’s revenue table reports $5.215 million in related-party revenue; a separate note reports $5.0 million from PrognomiQ plus $0.3 million from another related-party customer.
- Stock-based compensation was $33.7 million, including $4.8 million of incremental expense from repricing certain employee options and $0.9 million related to modification of executive awards.
- Available-for-sale investments had $1.3 million of unrealized losses at year-end, which the company considered temporary and not attributable to credit risk; no investment impairment charge was recorded.
- Seer’s investment in PrognomiQ was reduced to zero carrying value after recognizing its share of PrognomiQ’s losses. Seer retained approximately 15% ownership and continued supplying it with products and services.
Outlook, risks and contingencies
Seer provided no specific revenue, earnings or cash-flow guidance in the supplied filing text. Management expects to increase spending on commercialization, sales and support, research and development, manufacturing capacity and public-company operations. It expects a second Proteograph assay to be available in 2023. Its commercial strategy includes expanding customer adoption and consumables utilization, growing international distribution, and developing service and research partnerships.
Principal risks include the early stage of commercialization and uncertain market adoption; ongoing losses and potential future financing needs; customer and revenue concentration, particularly dependence on PrognomiQ; competition and uncertainty about market size; reliance on Hamilton Company for instrument manufacturing and on selected suppliers; manufacturing scale, product quality and performance risks; and evolving regulatory requirements if RUO products are deemed intended for diagnostic use or if Seer pursues clinical applications. Other disclosed risks include intellectual-property challenges, research-funding constraints, macroeconomic and supply-chain disruption, cybersecurity and privacy compliance, and retaining key personnel. Seer reported no material legal proceedings and no subsequent events requiring financial-statement recognition or disclosure through March 6, 2023.
The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not provide an internal-control attestation.
Key facts for investors to verify
- Whether instrument shipments convert into sustained installations, customer utilization and recurring consumables revenue.
- How much revenue and receivables continue to depend on PrognomiQ and other concentrated customers, and the terms and collectability of related-party balances.
- Whether gross margin improves as production scales, given FY 2022’s lower margin and rising cost of revenue.
- Cash burn, investment maturities, committed spending and the timing of any additional financing needs relative to management’s stated liquidity runway.
- Progress in validating product performance and adoption, and any regulatory implications of customer diagnostic use of products labeled for research use only.
- Potential dilution and compensation costs from outstanding options and RSUs, including the effects of option repricing and future equity awards.